From StopAfib.org - For Afib Patients, By Afib Patients
As a patient, you probably see lots of hype-filled reports about various drugs. After a drug is approved, there’s an inevitable blitz of negative publicity which often scares people away from important new solutions that could help them. There has been so much news lately about Multaq (dronedarone), the drug designed to provide the benefits [...]
StopAfib.org interviews Dr. Peter Kowey See the full transcript at: www.stopafib.org In this video interview at Boston Atrial Fibrillation Symposium 2010, Dr. Peter Kowey talked about a number of exciting new things in the atrial fibrillation world, including the Cabana clinical trials, the Safari catheter ablation registry, dronedarone as a
In this video interview at Boston Atrial Fibrillation Symposium, Dr. Peter Kowey, President of the Main Line Health Heart Center, talked about a number of exciting new things in the atrial fibrillation world. His topics included the Cabana clinical trials, the Safari catheter ablation registry, dronedarone as a replacement for amiodarone, atrial selective drugs, and [...]
In this video from Boston Atrial Fibrillation Symposium 2010, Professor John Camm discusses the two newest antiarrhythmic drugs, dronedarone (Multaq®), which is now approved in the US and Europe for atrial fibrillation, and vernakalant, which is a year or two away. These antiarrhythmic (rhythm control) drugs help to put patients
The Atrial Fibrillation Association in the UK was shocked by the decision by the National Institute for Health and Clinical Excellence (NICE) to deny atrial fibrillation patients access to dronedarone, a medication that has been approved in the U.S. and Europe. AFA is conducting a campaign to make the voices of atrial fibrillation patients heard. [...]
At Boston Atrial Fibrillation Symposium 2010, Prof. John Camm talked about the two newest antiarrhythmic drugs for atrial fibrillation treatment, dronedarone (Multaq®) and vernakalant. These antiarrhythmic (rhythm control) drugs help to put patients back into normal sinus rhythm, or to keep them in it. See the video: Interview with Professor John Camm at Boston Atrial [...]
We hear from so many afib patients every day about the trials, tribulations, and fears regarding being on amiodarone, or their refusal to take it. Since the FDA approved Multaq® (dronedarone) recently, the most frequent question I’ve fielded has been “When will Multaq® be available?” That happened this week, and the excitement they have shared [...]
On March 18, 2009, StopAfib.org represented the atrial fibrillation patient community at the FDA Cardiovascular and Renal Drugs Advisory Committee hearings on a replacement for amiodarone. We greatly appreciate you sharing your many stories so that we could share your experiences with the FDA. I had promised to share my comments with the afib patient [...]
For those atrial fibrillation patients who are on amiodarone, or for those avoiding it, there is good news. Multaq® (dronedarone), a replacement for amiodarone, received priority review status from the US FDA. While amiodarone is among the most effective atrial fibrillation medications, it has major toxicity issues that dronedarone doesn’t display. Read more…
